Exogenous c-GMP derivatives do not induce platelet aggregation but rather inhibit it at high concentrations, challenging the hypothesis that c-GMP mediates platelet activation.
Answers are grounded in this paper and cite their sources.
Challenges c-GMP mediation of platelet activation in animal models; leaves open in vivo relevance and therapeutic translation.
The role of c-GMP in platelets has been studied by investigating the influence of c-GMP derivatives, such as N6-2′-0-dibutyryl c-GMP and 8-bromo c-GMP, on platelet function.Dibutyryl c-GMP (500μM-5μM) and bromo c-GMP (1mM-10μM) did not cause platelet aggregation and serotonin release. At high concentrations these agents inhibited platelet aggregation and serotonin release induced by ADP and epinephrine. At lower concentrations the effect of these agents on epinephrine-induced aggregation was sometimes stimulatory, but was significant.Furthermore, the possibility has been invesstigated that aggregation induced by arachidonate might be mediated by increase of c-GMP levels in platleets.Addition of 1mM arachidonate to platelet rich plasma rapidly caused aggregation and serotonin release, but incubation of platelets with arachidonate did not alter the basal level of c-GMP in platelets.These results do not support the hypothesis that c-GMP might play a regulatory role in inducing platelet aggregation and release reaction.
No takes yet. Share an insight, caveat, or question.
Ryo et al. (1977) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: